Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis:: Effects on cancer staging and patient survival

被引:100
作者
Trevisani, F
Cantarini, MC
Labate, AMM
De Notariis, S
Rapaccini, G
Farinati, F
Del Poggio, P
Di Nolfo, MA
Benvegnù, L
Zoli, M
Borzio, F
Bernardi, M
机构
[1] Univ Bologna, Dipartimento Med Interna, I-40138 Bologna, Italy
[2] Univ Bologna, Dipartimento Med Interna & Gastroenterol, I-40138 Bologna, Italy
[3] Catholic Univ Rome, Cattedra Med Interna 2, Rome, Italy
[4] Univ Padua, Cattedra Malattie Apparato Digerente, Padua, Italy
[5] Univ Padua, Dipartimento Med Clin & Sperimentale, Padua, Italy
[6] Osped Bolognini, Div Med, Seriate, Italy
[7] Osped Treviglio Caravaggio, Div Med, Treviglio, Italy
[8] Osped Fatebenfratelli, Unite Gastroenterol, Dipartimento Med, Milan, Italy
关键词
D O I
10.1111/j.1572-0241.2004.30137.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Surveillance of cirrhotic individuals for early detection of HCC, based on ultrasonography (US) and alpha(1)-fetoprotein (AFP) determination, is a recommended practice currently applied also to elderly patients. However, several age-related factors may jeopardize the results of surveillance in these patients. Aim of the study was to evaluate the benefit of surveillance for HCC in elderly individuals. METHODS: Multicenter retrospective study on 1,277 consecutive patients with HCC. The inclusion criteria were: underlying chronic liver disease, description of cancer stage, and modalities of its diagnosis. Among the 1,037 patients fulfilling these criteria, 363 aged greater than or equal to70 yr were considered. RESULTS: The tumor was detected during surveillance, based on US and AFP performed every 6-12 months, in 158 individuals (group 1), incidentally in 138 (group 2) and because of symptoms in 67 (group 3). Surveillance reduced the risk of dealing with an advanced cancer (odds ratio (95% Confidence Interval): 0.18 (0.09-0.37) vs group 3, and 0.29 (0.17-0.49) vs group 2). The frequency of effective treatments decreased from group 1 to group 3 (73%, 57%, and 31%, respectively). The main cause of death was HCC progression. The survival corrected for the lead time of group 1 (median: 24 months) was significantly better than the crude survival of group 3 (7 months; p = 0.003) and barely better than that of group 2 (21 months). The latter also showed a better prognosis with respect to group 3 (p = 0.018). CONCLUSIONS: Surveillance for HCC improves the survival of elderly cirrhotic patients by expanding the percentage of cancers amenable to effective treatments.
引用
收藏
页码:1470 / 1476
页数:7
相关论文
共 32 条
[1]   Hepatocellular carcinoma: Diagnosis and treatment [J].
Befeler, AS ;
Di Bisceglie, AM .
GASTROENTEROLOGY, 2002, 122 (06) :1609-1619
[2]   Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis [J].
Bolondi, L ;
Sofia, S ;
Siringo, S ;
Gaiani, S ;
Casali, A ;
Zironi, G ;
Piscaglia, F ;
Gramantieri, L ;
Zanetti, M ;
Sherman, M .
GUT, 2001, 48 (02) :251-259
[3]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[4]   Transarterial chemoembolization for unresectable hepatocellular carcinoma:: Meta-analysis of randomized controlled trials [J].
Cammà, C ;
Schepis, F ;
Orlando, A ;
Albanese, M ;
Shahied, L ;
Trevisani, F ;
Andreone, P ;
Craxì, A ;
Cottone, M .
RADIOLOGY, 2002, 224 (01) :47-54
[5]  
CASTELLS L, 1995, LIVER, V15, P159
[6]   CLINICAL-FEATURES AND PROGNOSIS OF HEPATOCELLULAR-CARCINOMA IN BRITAIN IN RELATION TO AGE [J].
COLLIER, JD ;
CURLESS, R ;
BASSENDINE, MF ;
JAMES, OFW .
AGE AND AGEING, 1994, 23 (01) :22-27
[7]  
Commissione Epatocarcinoma dell'Associazione Italiana per lo Studio del Fegato, 1998, EP LIN GUID DIAGN TE, P235
[8]   Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis [J].
Hoshida, Y ;
Ikeda, K ;
Kobayashi, M ;
Suzuki, Y ;
Tsubota, A ;
Saitoh, S ;
Arase, Y ;
Kobayashi, M ;
Murashima, N ;
Chayama, K ;
Kumada, H .
JOURNAL OF HEPATOLOGY, 1999, 31 (05) :860-866
[9]  
Irvine HD, 1998, LANCET, V351, P215, DOI 10.1016/S0140-6736(05)78177-0
[10]   ELIMINATION OF LEAD TIME BIAS IN ASSESSING THE EFFECT OF EARLY BREAST-CANCER DIAGNOSIS [J].
JACQUES, PF ;
HARTZ, SC ;
TUTHILL, RW ;
HOLLINGSWORTH, C .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1981, 113 (01) :93-97